According to Intra-Cellular Therapies's latest financial reports the company has a price-to-book ratio of 11.7.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 11.7 | 52.56% |
2022-12-31 | 7.64 | -25.13% |
2021-12-31 | 10.2 | 161.93% |
2020-12-31 | 3.90 | -60.11% |
2019-12-31 | 9.77 | 396.25% |
2018-12-31 | 1.97 | 13.16% |
2017-12-31 | 1.74 | 0.01% |
2016-12-31 | 1.74 | -64.33% |
2015-12-31 | 4.87 | 12.86% |
2014-12-31 | 4.32 | -69.19% |
2013-12-31 | 14.0 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Xencor XNCR | 1.88 | -84.00% | ๐บ๐ธ USA |
MediciNova MNOV | 1.16 | -90.08% | ๐บ๐ธ USA |
Curis CRIS | 4.70 | -59.92% | ๐บ๐ธ USA |